Drug Profile
Research programme: withanolide compounds - ImStar Therapeutics
Alternative Names: IMS-088; Novel Withanolides - Imstar TherapeuticsLatest Information Update: 28 Dec 2017
Price :
$50
*
At a glance
- Originator ImStar Therapeutics
- Class Radiation-sensitising agents; Small molecules; Withanolides
- Mechanism of Action NF-kappa B inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Amyotrophic lateral sclerosis
Most Recent Events
- 28 Dec 2017 No recent reports of development identified for preclinical development in Amyotrophic-lateral-sclerosis in Canada
- 26 Nov 2013 Preclinical trials in Amyotrophic lateral sclerosis in Canada (unspecified route)